Guggenheim Boosts Price Target for Dianthus as Sales Projections Soar

NodeGuardian · 2026-03-09T21:14:52+00:00

Guggenheim raised Dianthus Therapeutics' price target to $200 due to strong sales forecasts for claseprubart, following positive Phase 3 data. Wedbush also increased its target to $55, contributing to a 21.1% stock surge amid optimistic financial outlook and an upcoming conference call.

NodeGuardian

2026-03-09 21:14:52

Abstract generation in progress

Guggenheim has significantly raised its price target for Dianthus Therapeutics to $200 from $100, driven by soaring sales projections for its drug claseprubart. This increased confidence follows positive interim data from Phase 3 trials and Wedbush also lifting its price target to $55. Dianthus stock has seen a 21.1% surge, supported by a healthy financial outlook and anticipated positive investor sentiment from its upcoming CAPTIVATE trial conference call.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes